At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 55 enrolled
Drug / intervention
panobinostat +2 moredrug
Likely dose
panobinostat 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Multi-center, Single Arm, Open Label Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
In Brief
A Phase 2 clinical trial evaluating panobinostat, bortezomib, and 1 other intervention for Relapsed and Bortezomib Refractory Multiple Myeloma and 2 related conditions. Completed, enrolled 55 participants across 13 sites.
Detailed Summary
This study is designed to assess the effectiveness of the combination of Panobinostat plus Bortezomib and Dexamethasone in patients with relapsed and bortezomib refractory Multiple Myeloma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRelapsed and Bortezomib Refractory Multiple Myeloma, Refractory Multiple Myeloma, Multiple Myeloma in Relapse
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 2010
Enrollment StartJun 2010
Primary CompletionFeb 2014
TodayJul 2026
First PostedMar 10, 2010
Enrollment StartJun 1, 2010
Primary CompletionFeb 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 16.3 years ago
Interventions
panobinostatdrug
PAN 20 mg PO given TIW, weeks 1\&2 of each 3-week cycle;• BTZ 1.3 mg/m2 IV push given BIW weeks 1\&2 of each 3 week cycle (days 1,4,8 and 11);• Dex 20 mg PO given QIW, weeks 1\&2 of each 3-week cycle (days 1,2,4,5,8,9,11 and 12)
bortezomibdrug
dexamethasonedrug